Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: J Hypertens. 2012 Jan;30(1):87–96. doi: 10.1097/HJH.0b013e32834dde5f

Fig. 6.

Fig. 6

Peroxisome proliferator-activated receptor-γ (PPARγ) antagonist prevents telmisartan (Telm) amelioration of lipopolysaccharide (LPS)-induced tumor necrosis factor-α (TNFα) release. Monocytes pretreated for 1 h with 1 μmol/l PPARγ antagonist T0070907 (T007) were incubated for 1 h with 10 μmol/l Telm or 10 μmol/l PPARγ agonist troglitazone (Tgz) followed by 4 h incubation in the presence of 50 ng/ml LPS. Cumulative TNFα release was determined in culture medium by ELISA. Results are means ± SEM of three independent experiments and are expressed as a percentage of LPS-induced response. #P<0.05 vs. LPS; ###P<0.001 vs. LPS; *P<0.05 vs. LPS with Telm or LPS with Tgz.